Hepatic insulin expression improves glycemic control in type 1 diabetic rats

Hengjiang Dong, Nuria Morral, Robert McEvoy, Marcia Meseck, Swan N. Thung, Savio L C Woo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Low levels of hepatic insulin production have been shown to prevent lethal ketoacidosis associated with type 1 diabetes. To assess the beneficial effects of sustained hepatic production of insulin on glycemic control in type 1 diabetes, we have employed the adenovirus-mediated gene delivery system to transfer an engineered rat preproinsulin gene to the livers of streptozotocin-induced diabetic nude rats. Hepatic insulin production resulted in the reduction of blood glucose in treated diabetic rats, the degree of blood glucose reduction correlated with both the vector dose and the level of hepatic insulin expression. At moderate vector doses, 0.3-0.7 ng/ml of plasma insulin was produced in treated diabetic animals, resulting in significant reduction of nonfasting hyperglycemia and improvement in glucose tolerance. Furthermore, these animals maintained euglycemia after 12-h fast. At higher vector doses, greater than 1 ng/ml of plasma insulin was produced, completely reversing nonfasting hyperglycemia in treated rats. However, all of the treated animals developed severe hypoglycemia upon fasting. This study has defined the maximal tolerable level of hepatic insulin production that is sufficient to reduce the degree and ameliorate the adverse effects of nonfasting hyperglycemia without risk of fasting hypoglycemia in type 1 diabetic rats.

Original languageEnglish (US)
Pages (from-to)153-163
Number of pages11
JournalDiabetes Research and Clinical Practice
Volume52
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Insulin
Liver
Hyperglycemia
Type 1 Diabetes Mellitus
Hypoglycemia
Blood Glucose
Nude Rats
Gene Transfer Techniques
Ketosis
Streptozocin
Adenoviridae
Glucose
Genes

Keywords

  • Adenoviral vector
  • Hepatic insulin production
  • Hyperglycemia
  • Nude rats
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Hepatic insulin expression improves glycemic control in type 1 diabetic rats. / Dong, Hengjiang; Morral, Nuria; McEvoy, Robert; Meseck, Marcia; Thung, Swan N.; Woo, Savio L C.

In: Diabetes Research and Clinical Practice, Vol. 52, No. 3, 2001, p. 153-163.

Research output: Contribution to journalArticle

Dong, Hengjiang ; Morral, Nuria ; McEvoy, Robert ; Meseck, Marcia ; Thung, Swan N. ; Woo, Savio L C. / Hepatic insulin expression improves glycemic control in type 1 diabetic rats. In: Diabetes Research and Clinical Practice. 2001 ; Vol. 52, No. 3. pp. 153-163.
@article{6450e9c830fd42da88f2edf09254b3af,
title = "Hepatic insulin expression improves glycemic control in type 1 diabetic rats",
abstract = "Low levels of hepatic insulin production have been shown to prevent lethal ketoacidosis associated with type 1 diabetes. To assess the beneficial effects of sustained hepatic production of insulin on glycemic control in type 1 diabetes, we have employed the adenovirus-mediated gene delivery system to transfer an engineered rat preproinsulin gene to the livers of streptozotocin-induced diabetic nude rats. Hepatic insulin production resulted in the reduction of blood glucose in treated diabetic rats, the degree of blood glucose reduction correlated with both the vector dose and the level of hepatic insulin expression. At moderate vector doses, 0.3-0.7 ng/ml of plasma insulin was produced in treated diabetic animals, resulting in significant reduction of nonfasting hyperglycemia and improvement in glucose tolerance. Furthermore, these animals maintained euglycemia after 12-h fast. At higher vector doses, greater than 1 ng/ml of plasma insulin was produced, completely reversing nonfasting hyperglycemia in treated rats. However, all of the treated animals developed severe hypoglycemia upon fasting. This study has defined the maximal tolerable level of hepatic insulin production that is sufficient to reduce the degree and ameliorate the adverse effects of nonfasting hyperglycemia without risk of fasting hypoglycemia in type 1 diabetic rats.",
keywords = "Adenoviral vector, Hepatic insulin production, Hyperglycemia, Nude rats, Type 1 diabetes",
author = "Hengjiang Dong and Nuria Morral and Robert McEvoy and Marcia Meseck and Thung, {Swan N.} and Woo, {Savio L C}",
year = "2001",
doi = "10.1016/S0168-8227(01)00220-0",
language = "English (US)",
volume = "52",
pages = "153--163",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Hepatic insulin expression improves glycemic control in type 1 diabetic rats

AU - Dong, Hengjiang

AU - Morral, Nuria

AU - McEvoy, Robert

AU - Meseck, Marcia

AU - Thung, Swan N.

AU - Woo, Savio L C

PY - 2001

Y1 - 2001

N2 - Low levels of hepatic insulin production have been shown to prevent lethal ketoacidosis associated with type 1 diabetes. To assess the beneficial effects of sustained hepatic production of insulin on glycemic control in type 1 diabetes, we have employed the adenovirus-mediated gene delivery system to transfer an engineered rat preproinsulin gene to the livers of streptozotocin-induced diabetic nude rats. Hepatic insulin production resulted in the reduction of blood glucose in treated diabetic rats, the degree of blood glucose reduction correlated with both the vector dose and the level of hepatic insulin expression. At moderate vector doses, 0.3-0.7 ng/ml of plasma insulin was produced in treated diabetic animals, resulting in significant reduction of nonfasting hyperglycemia and improvement in glucose tolerance. Furthermore, these animals maintained euglycemia after 12-h fast. At higher vector doses, greater than 1 ng/ml of plasma insulin was produced, completely reversing nonfasting hyperglycemia in treated rats. However, all of the treated animals developed severe hypoglycemia upon fasting. This study has defined the maximal tolerable level of hepatic insulin production that is sufficient to reduce the degree and ameliorate the adverse effects of nonfasting hyperglycemia without risk of fasting hypoglycemia in type 1 diabetic rats.

AB - Low levels of hepatic insulin production have been shown to prevent lethal ketoacidosis associated with type 1 diabetes. To assess the beneficial effects of sustained hepatic production of insulin on glycemic control in type 1 diabetes, we have employed the adenovirus-mediated gene delivery system to transfer an engineered rat preproinsulin gene to the livers of streptozotocin-induced diabetic nude rats. Hepatic insulin production resulted in the reduction of blood glucose in treated diabetic rats, the degree of blood glucose reduction correlated with both the vector dose and the level of hepatic insulin expression. At moderate vector doses, 0.3-0.7 ng/ml of plasma insulin was produced in treated diabetic animals, resulting in significant reduction of nonfasting hyperglycemia and improvement in glucose tolerance. Furthermore, these animals maintained euglycemia after 12-h fast. At higher vector doses, greater than 1 ng/ml of plasma insulin was produced, completely reversing nonfasting hyperglycemia in treated rats. However, all of the treated animals developed severe hypoglycemia upon fasting. This study has defined the maximal tolerable level of hepatic insulin production that is sufficient to reduce the degree and ameliorate the adverse effects of nonfasting hyperglycemia without risk of fasting hypoglycemia in type 1 diabetic rats.

KW - Adenoviral vector

KW - Hepatic insulin production

KW - Hyperglycemia

KW - Nude rats

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0035032259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035032259&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(01)00220-0

DO - 10.1016/S0168-8227(01)00220-0

M3 - Article

C2 - 11323084

AN - SCOPUS:0035032259

VL - 52

SP - 153

EP - 163

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -